vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and IDEAYA Biosciences, Inc. (IDYA). Click either name above to swap in a different company.
IDEAYA Biosciences, Inc. is the larger business by last-quarter revenue ($207.8M vs $196.0M, roughly 1.1× Axsome Therapeutics, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs -14.6%, a 71.9% gap on every dollar of revenue. IDEAYA Biosciences, Inc. produced more free cash flow last quarter ($142.2M vs $-18.7M).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
AXSM vs IDYA — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $207.8M |
| Net Profit | $-28.6M | $119.2M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | 52.2% |
| Net Margin | -14.6% | 57.4% |
| Revenue YoY | 65.0% | — |
| Net Profit YoY | 61.9% | 330.1% |
| EPS (diluted) | $-0.55 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | — | ||
| Q3 25 | $171.0M | $207.8M | ||
| Q2 25 | $150.0M | — | ||
| Q1 25 | $121.5M | — | ||
| Q4 24 | $118.8M | — | ||
| Q3 24 | $104.8M | $0 | ||
| Q2 24 | $87.2M | $0 | ||
| Q1 24 | $75.0M | $0 |
| Q4 25 | $-28.6M | — | ||
| Q3 25 | $-47.2M | $119.2M | ||
| Q2 25 | $-48.0M | — | ||
| Q1 25 | $-59.4M | — | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $-64.6M | $-51.8M | ||
| Q2 24 | $-79.3M | $-52.8M | ||
| Q1 24 | $-68.4M | $-39.6M |
| Q4 25 | -13.8% | — | ||
| Q3 25 | -27.0% | 52.2% | ||
| Q2 25 | -24.5% | — | ||
| Q1 25 | -46.9% | — | ||
| Q4 24 | -61.1% | — | ||
| Q3 24 | -59.8% | — | ||
| Q2 24 | -89.5% | — | ||
| Q1 24 | -89.7% | — |
| Q4 25 | -14.6% | — | ||
| Q3 25 | -27.6% | 57.4% | ||
| Q2 25 | -32.0% | — | ||
| Q1 25 | -48.9% | — | ||
| Q4 24 | -63.1% | — | ||
| Q3 24 | -61.7% | — | ||
| Q2 24 | -91.0% | — | ||
| Q1 24 | -91.1% | — |
| Q4 25 | $-0.55 | — | ||
| Q3 25 | $-0.94 | $1.33 | ||
| Q2 25 | $-0.97 | — | ||
| Q1 25 | $-1.22 | — | ||
| Q4 24 | $-1.54 | — | ||
| Q3 24 | $-1.34 | $-0.60 | ||
| Q2 24 | $-1.67 | $-0.68 | ||
| Q1 24 | $-1.44 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $786.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $1.1B |
| Total Assets | $689.8M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | — | ||
| Q3 25 | $325.3M | $786.9M | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | $920.0M | ||
| Q2 24 | $315.7M | $701.7M | ||
| Q1 24 | $331.4M | $698.8M |
| Q4 25 | $88.3M | — | ||
| Q3 25 | $73.7M | $1.1B | ||
| Q2 25 | $73.1M | — | ||
| Q1 25 | $53.2M | — | ||
| Q4 24 | $57.0M | — | ||
| Q3 24 | $92.9M | $1.2B | ||
| Q2 24 | $102.9M | $931.7M | ||
| Q1 24 | $144.0M | $935.3M |
| Q4 25 | $689.8M | — | ||
| Q3 25 | $669.3M | $1.2B | ||
| Q2 25 | $639.8M | — | ||
| Q1 25 | $596.7M | — | ||
| Q4 24 | $568.5M | — | ||
| Q3 24 | $561.5M | $1.2B | ||
| Q2 24 | $548.2M | $973.7M | ||
| Q1 24 | $545.7M | $961.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $142.2M |
| Free Cash FlowOCF − Capex | $-18.7M | $142.2M |
| FCF MarginFCF / Revenue | -9.6% | 68.4% |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $13.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $1.0M | $142.2M | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.4M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.6M | $-49.2M | ||
| Q2 24 | $-30.1M | $-32.9M | ||
| Q1 24 | $-53.5M | $-43.8M |
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $988.0K | $142.2M | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.7M | $-49.7M | ||
| Q2 24 | $-30.2M | $-33.9M | ||
| Q1 24 | $-53.6M | $-45.1M |
| Q4 25 | -9.6% | — | ||
| Q3 25 | 0.6% | 68.4% | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | — | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -34.6% | — | ||
| Q1 24 | -71.4% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.19× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
